Patents by Inventor Roger Beerli

Roger Beerli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12121527
    Abstract: The present invention relates to antibody drug conjugates (ADCs) presenting improved properties of in vivo tolerability.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: October 22, 2024
    Assignee: NBE-THERAPEUTICS AG
    Inventors: Ulf Grawunder, Roger Beerli, Remy Gebleux
  • Publication number: 20240100180
    Abstract: The invention provides an ADC based on an antibody binding to CLDN18.2, wherein the antibody or fragment thereof exhibits increased binding to tumor tissue expressing CLDN18.2 over healthy tissue expressing CLDN18.2.
    Type: Application
    Filed: December 23, 2021
    Publication date: March 28, 2024
    Inventors: Lukas Bammert, Lenka Kyrych Sadilkova, Simona Hoskova, Iva Valentova, Lorenz Waldmeier, Roger Beerli, Ulrich Moebius
  • Publication number: 20240034783
    Abstract: The invention provides tumor specific anti-CLDN18.2 antibodies or fragments thereof. The antibodies or fragments thereof exhibit increased binding to tumor tissue expressing CLDN 18.2 over healthy tissue expressing CLDN18.2. Further, the antibodies do not exhibit cross-reactivity to CLDN18.1. The invention also provides nucleic acids, vectors, host cells and medical uses.
    Type: Application
    Filed: December 23, 2020
    Publication date: February 1, 2024
    Inventors: Lukas Bammert, Lenka Kyrych Sadilkova, Simona Hoskova, Iva Valentova, Lorenz Waldmeier, Roger Beerli, Ulrich Moebius
  • Patent number: 11845793
    Abstract: The present invention relates to a human or humanized antibody, or an antibody-based binding protein, modified antibody format retaining target binding capacity, antibody derivative or fragment retaining target binding capacity, which targets Receptor tyrosine kinase-like orphan receptor-1 (ROR1). It further relates to bi- or multispecific antibodies, to Immunoligand-Drug Conjugates, to Chimeric Antigen Receptors and to T-cells comprising such Chimeric Antigen Receptors.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: December 19, 2023
    Assignee: NBE-THERAPEUTICS AG
    Inventors: Lorenz Waldmeier, Ulf Grawunder, Roger Beerli
  • Publication number: 20230030674
    Abstract: The invention provides humanized antibodies binding to CLDN18.2 with a high affinity. Further, the antibodies do not exhibit cross-reactivity to CLDN18.1. The invention also provides nucleic acids, vectors, host cells and medical uses.
    Type: Application
    Filed: December 7, 2020
    Publication date: February 2, 2023
    Inventors: Lukas Bammert, Lenka Kyrych Sadilkova, Lorenz Waldmeier, Roger Beerli, Ulrich Moebius
  • Publication number: 20220372143
    Abstract: The present invention relates to fully human antibodies and conjugates thereof, which specifically bind to the extracellular domain of receptor tyrosine kinase-like orphan receptor 2 (ROR2).
    Type: Application
    Filed: July 22, 2022
    Publication date: November 24, 2022
    Inventors: Ulf GRAWUNDER, Roger BEERLI, Ina HELLMANN, Lorenz WALDMEIER
  • Patent number: 11447546
    Abstract: The present invention relates to fully human antibodies and conjugates thereof, which specifically bind to the extracellular domain of receptor tyrosine kinase-like orphan receptor 2 (ROR2).
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: September 20, 2022
    Assignee: NBE-THERAPEUTICS AG
    Inventors: Ulf Grawunder, Roger Beerli, Ina Hellmann, Lorenz Waldmeier
  • Publication number: 20220153839
    Abstract: The invention provides antibodies, antibody drug conjugates, antibody-based fragments or antibody fragments (antigen-binding fragments), as well as antibody drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize human ROR1 and related compositions. Also provided in the invention are methods of using such antibodies in various diagnostic and therapeutic applications.
    Type: Application
    Filed: December 28, 2021
    Publication date: May 19, 2022
    Inventors: Christoph RADER, Haiyong PENG, Roger BEERLI, Lorenz WALDMEIER, Ulf GRAWUNDER
  • Patent number: 11242388
    Abstract: The invention provides antibodies, antibody drug conjugates, antibody-based fragments or antibody fragments (antigen-binding fragments), as well as antibody drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize human ROR1 and related compositions. Also provided in the invention are methods of using such antibodies in various diagnostic and therapeutic applications.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: February 8, 2022
    Assignees: NBE-Therapeutics AG, The Scripps Research Institute
    Inventors: Christoph Rader, Haiyong Peng, Roger Beerli, Lorenz Waldmeier, Ulf Grawunder
  • Publication number: 20210379194
    Abstract: The present invention relates to binding protein-toxin conjugates comprising one or more anthracycline toxin moieties, and the use thereof in immunooncological applications.
    Type: Application
    Filed: October 11, 2019
    Publication date: December 9, 2021
    Inventors: Ulf GRAWUNDER, Roger BEERLI, Lorenz WALDMEIER, Francesca PRETTO
  • Publication number: 20210379196
    Abstract: The present invention relates to a method for producing a conjugate of two substrates, the method comprising the steps of (a) providing two substrates, each substrate being independently selected from the one or more of the groups consisting of small molecules, and proteins, and (b) enzymatically conjugating the two substrates using a sortase F enzyme, or a catalytic domain thereof. One substrate comprises a sortase F recognition motif, while the other substrate comprises at least one motif selected from a Glyn motif, an Alan motif, or a motif consisting of a mixture of Ala and Gly residues the motif totaling n residues, where n is an integer from ?1 to ?21. The reaction takes place in an aqueous reaction medium comprising a salt concentration of from about ?0.01 to ?3 M, thereby producing a conjugated product of the two substrates.
    Type: Application
    Filed: November 4, 2019
    Publication date: December 9, 2021
    Inventors: Ulf GRAWUNDER, Roger BEERLI, Remy GEBLEUX, Chasper PUORGER, Salvatore DI GIROLAMO, Georg LIPPS
  • Publication number: 20210139579
    Abstract: The present invention relates to a multi-specific product comprising a first entity comprising an antigen-binding domain that binds to the same ROR1 epitope as and/or competes for ROR1 binding with an antibody comprising a heavy chain variable region sequence shown in SEQ ID NO. 2 and a light chain variable region sequence shown in SEQ ID NO. 3; and a second entity comprising an antigen-binding domain that binds to a different target or ROR1 epitope than, and/or does not compete for binding with the antibody comprising a heavy chain variable region sequence shown in SEQ ID NO. 2 and a light chain variable region sequence shown in SEQ ID NO. 3.
    Type: Application
    Filed: July 20, 2018
    Publication date: May 13, 2021
    Inventors: Ulf GRAWUNDER, Roger BEERLI, Lorenz WALDMEIER
  • Publication number: 20210023103
    Abstract: The present invention relates to antibody drug conjugates (ADCs) presenting improved properties of in vivo tolerability.
    Type: Application
    Filed: July 10, 2020
    Publication date: January 28, 2021
    Inventors: Ulf GRAWUNDER, Roger BEERLI, Remy GEBLEUX
  • Publication number: 20200354449
    Abstract: The present invention relates to fully human antibodies and conjugates thereof, which specifically bind to the extracellular domain of receptor tyrosine kinase-like orphan receptor 2 (ROR2).
    Type: Application
    Filed: July 20, 2018
    Publication date: November 12, 2020
    Inventors: Ulf Grawunder, Roger Beerli, Ina Hellmann, Lorenz Waldmeier
  • Publication number: 20200299381
    Abstract: The invention provides antibodies, antibody drug conjugates, antibody-based fragments or antibody fragments (antigen-binding fragments), as well as antibody drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize human ROR1 and related compositions. Also provided in the invention are methods of using such antibodies in various diagnostic and therapeutic applications.
    Type: Application
    Filed: February 28, 2020
    Publication date: September 24, 2020
    Inventors: Christoph Rader, Haiyong Peng, Roger Beerli, Lorenz Waldmeier, Ulf Grawunder
  • Patent number: 10758556
    Abstract: The present invention relates to antibody drug conjugates (ADCs) presenting improved properties of in vivo tolerability.
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: September 1, 2020
    Assignee: NBE-THERAPEUTICS AG
    Inventors: Ulf Grawunder, Roger Beerli, Remy Gebleux
  • Patent number: 10618959
    Abstract: The invention provides antibodies, antibody drug conjugates, antibody-based fragments or antibody fragments (antigen-binding fragments), as well as antibody drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize human ROR1 and related compositions. Also provided in the invention are methods of using such antibodies in various diagnostic and therapeutic applications.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: April 14, 2020
    Assignees: NBE-Therapeutics AG, The Scripps Research Institute
    Inventors: Christoph Rader, Haiyong Peng, Roger Beerli, Lorenz Waldmeier, Ulf Grawunder
  • Publication number: 20190381079
    Abstract: The present invention relates to antibody drug conjugates (ADCs) presenting improved properties of in vivo tolerability.
    Type: Application
    Filed: August 6, 2019
    Publication date: December 19, 2019
    Inventors: Ulf GRAWUNDER, Roger BEERLI, Remy GEBLEUX
  • Publication number: 20190153092
    Abstract: The present invention relates to a human or humanized antibody, or an antibody-based binding protein, modified antibody format retaining target binding capacity, antibody derivative or fragment retaining target binding capacity, which targets Receptor tyrosine kinase-like orphan receptor-1 (ROR1). It further relates to bi- or multispecific antibodies, to Immunoligand-Drug Conjugates, to Chimeric Antigen Receptors and to T-cells comprising such Chimeric Antigen Receptors.
    Type: Application
    Filed: October 31, 2016
    Publication date: May 23, 2019
    Inventors: Lorenz WALDMEIER, Ulf GRAWUNDER, Roger BEERLI
  • Publication number: 20190112385
    Abstract: The present invention relates to a human or humanized antibody, or an antibody-based binding protein, modified antibody format retaining target binding capacity, antibody derivative or fragment retaining target binding capacity, which targets Mesothelin (MN). It further relates to bi- or multispecific antibodies, to Immunoligand-Drug Conjugates, to Chimeric Antigen Receptors and to T-cells comprising such Chimeric Antigen Receptors.
    Type: Application
    Filed: October 31, 2016
    Publication date: April 18, 2019
    Applicant: NBE-THERAPEUTICS AG
    Inventors: Ina HELLMANN, Lorenz WALDMEIER, Ulf GRAWUNDER, Roger BEERLI